Treadwell Therapeutics, Inc Report issue

For profit Phase 2
Founded: New York NY United States (2019)

Organization Overview

First Clinical Trial
2020
NCT04521413
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Treadwell Therapeutics, Inc

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 7